Avicenna Biosciences website screenshot

Avicenna Biosciences

Avicenna Biosciences, Inc. is a Durham, North Carolina drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate optimization process for small molecule drug development. Founded in 2020 and led by president and CEO Chris Meldrum, the company applies computational screening of candidate molecules for drug-like properties to the "last mile" of small molecule discovery, targeting neurodegenerative disease programs including Rho kinase inhibitors for Parkinson's disease and ALS. Avicenna raised a seed round led by DCVC Bio and has signed research collaborations with partners such as Molecure S.A. The company publishes no public developer portal, API, or machine-readable interface as of this enrichment pass; it is catalogued here as an AI-for-drug-discovery company profile rather than an API provider.

Avicenna Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biosciences, Life Sciences, Biotechnology, and Venture Backed.

Avicenna Biosciences’ developer surface includes product news and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiosciencesLife SciencesBiotechnologyVenture BackedDCVC PortfolioDrug DiscoveryMachine LearningMedicinal ChemistrySmall MoleculeNeurodegenerative DiseaseArtificial Intelligence

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/avicenna-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Avicenna Biosciences Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 4

The organization behind the API

Website
Website
 About
About
 News
News
 LinkedIn
LinkedIn

Other 1

Properties that don't map to a standard resource type

Team
Team

Source (apis.yml)

apis.yml Raw ↑ 
aid: avicenna-biosciences
name: Avicenna Biosciences
description: Avicenna Biosciences, Inc. is a Durham, North Carolina drug development company using machine learning-enhanced
  medicinal chemistry to accelerate the lead-to-candidate optimization process for small molecule drug development. Founded
  in 2020 and led by president and CEO Chris Meldrum, the company applies computational screening of candidate molecules for
  drug-like properties to the "last mile" of small molecule discovery, targeting neurodegenerative disease programs including
  Rho kinase inhibitors for Parkinson's disease and ALS. Avicenna raised a seed round led by DCVC Bio and has signed research
  collaborations with partners such as Molecure S.A. The company publishes no public developer portal, API, or machine-readable
  interface as of this enrichment pass; it is catalogued here as an AI-for-drug-discovery company profile rather than an API
  provider.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://images.ctfassets.net/5je0qvum28n8/5gAbv4QZiCZIcbSssrG929/bf3447db4edfba83dea17dbd7abcb123/default-share-image.jpg?w=1200&h=630&q=65
url: https://raw.githubusercontent.com/api-evangelist/avicenna-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biosciences
- Life Sciences
- Biotechnology
- Venture Backed
- DCVC Portfolio
- Drug Discovery
- Machine Learning
- Medicinal Chemistry
- Small Molecule
- Neurodegenerative Disease
- Artificial Intelligence
apis: []
common:
- type: Website
  url: https://www.avicenna-bio.com/
- type: About
  url: https://www.avicenna-bio.com/approach
- type: Team
  url: https://www.avicenna-bio.com/team
- type: News
  url: https://www.avicenna-bio.com/news
- type: LinkedIn
  url: https://www.linkedin.com/company/avicenna-biosciences
- type: DomainSecurity
  url: security/avicenna-biosciences-domain-security.yml
- type: LLMsTxt
  url: llms/avicenna-biosciences-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 3
  pass: local-v1